Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 28Neoplasms 3Neoplasm Metastasis 3Metastatic Castration-Resistant Prostate Cancer (mCRPC) 2Urogenital Neoplasms 1Prostatic Diseases 1Prostate Cancer Metastatic 1Neoplasms, Glandular and Epithelial 1Metastatic Castration-resistant Prostate Cancer 1Metastatic Castrate-resistant Prostate Cancer 1Hormone-Refractory Prostate Cancer 1Genital Neoplasms, Male 1Castrate Refractory Metastatic Prostate Cancer (mCRPC) 1Carcinoma 1Adenocarcinoma of the Prostate 1Adenocarcinoma 1

Interventions

Abiraterone Acetate 7enzalutamide 6olaparib 5Prednisone 5Pluvicto 5Docetaxel 5radium Ra 223 dichloride 4darolutamide 4cabazitaxel 3Prednisolone 3testosterone 17 beta-cypionate 2fludarabine 2abiraterone 2Nivolumab 2Cyclophosphamide 2Androgen Antagonists 2sipuleucel-T 1rucaparib 1poly ICLC 1pamiparib 1niraparib 1lactitol 1fludarabine phosphate 1fluciclovine F-18 1enfortumab vedotin 1ebastine 1copanlisib 1cabozantinib 1bempegaldesleukin 1avelumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Metastatic Castration-resistant Prostate Cancer × sipuleucel-T × Clear all
NCT06100705 2025-11-04

Sipuleucel-T Combined With Bipolar Androgen Therapy in Men With mCRPC

Yale University

Phase 2 Recruiting
26 enrolled
Genitourinary

Metastatic Castration-resistant Prostate Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡